Black Diamond Therapeutics Reports Promising Phase 2 Data for Silevertinib in EGFR-Mutant Cancers
Key Insights
Black Diamond Therapeutics reported 60% objective response rate and 86% CNS response rate for silevertinib (search) in frontline non-classical EGFR (search)-mutant NSCLC patients.
The company plans to initiate a randomized Phase 2 trial for silevertinib (search) in newly diagnosed EGFR (search)-altered glioblastoma in Q2 2026.
Updated clinical data including preliminary duration of response and progression-free survival data will be presented at a medical meeting in Q2 2026.
Black Diamond Therapeutics announced encouraging Phase 2 trial results for silevertinib (search), its brain-penetrant fourth-generation EGFR (search) inhibitor, demonstrating significant clinical activity in patients with non-classical EGFR-mutant non-small cell lung cancer (NSCLC). The company also outlined plans to expand development into glioblastoma (GBM) while maintaining a strong financial position through 2028.
Clinical Efficacy in NSCLC Shows Promise
In December 2025, Black Diamond disclosed initial data from its Phase 2 trial of silevertinib (search) in frontline NSCLC patients harboring non-classical epidermal growth factor receptor (EGFR (search)) mutations. The results demonstrated a 60% objective response rate (ORR by RECIST 1.1), 86% central nervous system (CNS) ORR (by RANO-BM), and 91% disease control rate (DCR) as of a November 3, 2025 data cutoff. Importantly, no new safety signals were observed during the trial.
"We continue to focus on advancing silevertinib (search) for the treatment of patients with EGFRm NSCLC and EGFR (search) altered GBM," said Mark Velleca, M.D., Ph.D., President and Chief Executive Officer of Black Diamond Therapeutics. "We look forward to presenting updated results from the Phase 2 NSCLC trial in both the frontline and recurrent settings, including preliminary DOR and PFS data for frontline patients, at a medical meeting in the second quarter of 2026."
Expansion into Glioblastoma
Black Diamond is preparing to initiate a randomized Phase 2 trial of silevertinib (search) in patients with newly diagnosed EGFR (search)-altered GBM in the second quarter of 2026 (NCT07326566). This expansion leverages silevertinib's brain-penetrant properties, designed to address central nervous system disease.
The company's MasterKey therapies are engineered to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and maintain brain penetration for treating CNS disease.
Upcoming Clinical Milestones
Black Diamond anticipates presenting updated clinical data from its Phase 2 trial in patients with non-classical EGFR (search) NSCLC in both recurrent and frontline settings at a medical meeting in Q2 2026 (NCT05256290). This presentation will include preliminary duration of response (DOR) and progression-free survival (PFS) data for frontline EGFRm patients.
The company continues to explore potential partnership opportunities to advance silevertinib (search) into pivotal development, indicating confidence in the drug's commercial potential.
Financial Position Supports Extended Development
Black Diamond ended 2025 with approximately $128.7 million in cash, cash equivalents, and investments, compared to $98.6 million as of December 31, 2024. The company believes this cash position is sufficient to fund anticipated operating expenses and capital expenditure requirements into the second half of 2028.
The improved financial position reflects operational efficiencies and strategic focus. Research and development expenses decreased to $33.6 million for 2025 from $51.3 million in 2024, primarily due to workforce efficiencies and the outlicensing of BDTX-4933 to increase focus on silevertinib (search) development. General and administrative expenses also declined to $16.6 million in 2025 from $27.5 million in 2024.
Net cash provided by operations was $29.6 million for 2025, a significant improvement from net cash used in operations of $62.3 million in 2024. The company reported net income of $22.4 million for 2025, compared to a net loss of $69.7 million in 2024.